Realheart Has Been Granted an Additional Loan From Almi

Press Release 10 October, 2022

Realheart has been granted an additional loan from Almi of SEK 7.6 million, which will aid in securing a continuos rapid product development targeting clinical trials.  

”It is a realtively small sum considering our total financing need, but we always evaluate options for additional funding, in order to extend the duration for our investors capital. Not all companies qualify and we are very greatful for the support from Almi," said Realheart CEO Ina Laura Perkins.

For more information please contact:

Ina Laura Perkins, CEO

Phone: +46(0)70 406 49 21 

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30 732, email: ca@skmg.se

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart® TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation. A unique concept in the medical technology world.